newsfilter
← Latest News
Business Wire·

Gemini Therapeutics Provides GEM103 Program Update

Gemini Therapeutics, Inc. (NASDAQ:GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today announced updates from its ongoing phase 2a clinical studies of G